Sort by
Items per page

Send to

Choose Destination

Search results

Items: 16


Immunogenicity of pneumococcal conjugate vaccine formulations containing pneumococcal proteins, and immunogenicity and reactogenicity of co-administered routine vaccines - A phase II, randomised, observer-blind study in Gambian infants.

Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Owiafe PK, Worwui A, Idoko OT, Owolabi O, Kampmann B, Greenwood BM, Alderson M, Traskine M, Swinnen K, Verlant V, Dobbelaere K, Borys D.

Vaccine. 2019 May 1;37(19):2586-2599. doi: 10.1016/j.vaccine.2019.03.033. Epub 2019 Apr 8.


Viral Hepatitis Endemicity and Trends among an Asymptomatic Adult Population in Ho: A 5-Year Retrospective Study at the Ho Municipal Hospital, Ghana.

Lokpo SY, Osei-Yeboah J, Norgbe GK, Owiafe PK, Ayroe F, Ussher FA, Dakorah MP, Gameli Deku J, Manaphraim NYB, Akomanin Asiamah E, Ntoni T, Senyo Kwasi Nyamadi P, Yiadom Boakye E, Avorkliyah R.

Hepat Res Treat. 2017;2017:6174743. doi: 10.1155/2017/6174743. Epub 2017 Nov 6.


Mycobacterium tuberculosis Infection in Close Childhood Contacts of Adults with Pulmonary Tuberculosis is Increased by Secondhand Exposure to Tobacco.

Adetifa IMO, Kendall L, Donkor S, Lugos MD, Hammond AS, Owiafe PK, Ota MOC, Brookes RH, Hill PC.

Am J Trop Med Hyg. 2017 Aug;97(2):429-432. doi: 10.4269/ajtmh.16-0611. Epub 2017 Jul 19.


Efficacy of a novel, protein-based pneumococcal vaccine against nasopharyngeal carriage of Streptococcus pneumoniae in infants: A phase 2, randomized, controlled, observer-blind study.

Odutola A, Ota MOC, Antonio M, Ogundare EO, Saidu Y, Foster-Nyarko E, Owiafe PK, Ceesay F, Worwui A, Idoko OT, Owolabi O, Bojang A, Jarju S, Drammeh I, Kampmann B, Greenwood BM, Alderson M, Traskine M, Devos N, Schoonbroodt S, Swinnen K, Verlant V, Dobbelaere K, Borys D.

Vaccine. 2017 May 2;35(19):2531-2542. doi: 10.1016/j.vaccine.2017.03.071. Epub 2017 Apr 4.


Broad adaptive immune responses to M. tuberculosis antigens precede TST conversion in tuberculosis exposed household contacts in a TB-endemic setting.

Buchwald UK, Adetifa IM, Bottomley C, Owiafe PK, Donkor S, Bojang AL, Sutherland JS.

PLoS One. 2014 Dec 30;9(12):e116268. doi: 10.1371/journal.pone.0116268. eCollection 2014.


Safety and immunogenicity of the M72/AS01 candidate tuberculosis vaccine when given as a booster to BCG in Gambian infants: an open-label randomized controlled trial.

Idoko OT, Owolabi OA, Owiafe PK, Moris P, Odutola A, Bollaerts A, Ogundare E, Jongert E, Demoiti├ę MA, Ofori-Anyinam O, Ota MO.

Tuberculosis (Edinb). 2014 Dec;94(6):564-78. doi: 10.1016/ Epub 2014 Aug 9.


Diagnostic utility of QuantiFERON-TB gold in-tube in active pulmonary Tuberculosis in Nigeria.

Adewole OO, Erhabor GE, Sogaolu MO, Onipede AO, Owiafe PK, Awopeju FO, Ota MO.

West Afr J Med. 2013 Jul-Sep;32(3):180-5. English, French.


Interferon-╬│ ELISPOT as a biomarker of treatment efficacy in latent tuberculosis infection: a clinical trial.

Adetifa IM, Ota MO, Jeffries DJ, Lugos MD, Hammond AS, Battersby NJ, Owiafe PK, Donkor SD, Antonio M, Ibanga HB, Brookes RH, Aka P, Walton R, Adegbola RA, Hill PC.

Am J Respir Crit Care Med. 2013 Feb 15;187(4):439-45. doi: 10.1164/rccm.201208-1352OC. Epub 2012 Dec 6.


A new TB vaccine, MVA85A, induces durable antigen-specific responses 14 months after vaccination in African infants.

Odutola AA, Owolabi OA, Owiafe PK, McShane H, Ota MO.

Vaccine. 2012 Aug 17;30(38):5591-4. doi: 10.1016/j.vaccine.2012.06.054. Epub 2012 Jun 27.


Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.

Ota MO, Odutola AA, Owiafe PK, Donkor S, Owolabi OA, Brittain NJ, Williams N, Rowland-Jones S, Hill AV, Adegbola RA, McShane H.

Sci Transl Med. 2011 Jun 22;3(88):88ra56. doi: 10.1126/scitranslmed.3002461.


Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.

Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Jeffries DJ, Donkor SA, Fletcher HA, Hammond AS, Lienhardt C, Adegbola RA, McShane H, Hill AV.

PLoS One. 2008 Aug 13;3(8):e2921. doi: 10.1371/journal.pone.0002921. Erratum in: PLoS One. 2011;6(2). doi:10.1371/annotation/5284a0b6-62a9-484e-80a4-a08c59b3b17c.


The effect of tuberculin skin test and BCG vaccination on the expansion of PPD-specific IFN-gamma producing cells ex vivo.

Ota MO, Brookes RH, Hill PC, Owiafe PK, Ibanga HB, Donkor S, Awine T, McShane H, Adegbola RA.

Vaccine. 2007 Dec 17;25(52):8861-7. Epub 2007 Oct 31.


ESAT-6 and CFP-10 can be combined to reduce the cost of testing for Mycobacterium tuberculosis infection, but CFP-10 responses associate with active disease.

Fox A, Jeffries DJ, Hill PC, Hammond AS, Lugos MD, Jackson-Sillah D, Donkor SA, Owiafe PK, McAdam KP, Brookes RH.

Trans R Soc Trop Med Hyg. 2007 Jul;101(7):691-8. Epub 2007 Apr 16.


Early clinical trials with a new tuberculosis vaccine, MVA85A, in tuberculosis-endemic countries: issues in study design.

Ibanga HB, Brookes RH, Hill PC, Owiafe PK, Fletcher HA, Lienhardt C, Hill AV, Adegbola RA, McShane H.

Lancet Infect Dis. 2006 Aug;6(8):522-8. Review.


Quantitative T cell assay reflects infectious load of Mycobacterium tuberculosis in an endemic case contact model.

Hill PC, Fox A, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Corrah T, Adegbola RA, McAdam KP, Brookes RH.

Clin Infect Dis. 2005 Jan 15;40(2):273-8. Epub 2004 Dec 20.


Large-scale evaluation of enzyme-linked immunospot assay and skin test for diagnosis of Mycobacterium tuberculosis infection against a gradient of exposure in The Gambia.

Hill PC, Brookes RH, Fox A, Fielding K, Jeffries DJ, Jackson-Sillah D, Lugos MD, Owiafe PK, Donkor SA, Hammond AS, Otu JK, Corrah T, Adegbola RA, McAdam KP.

Clin Infect Dis. 2004 Apr 1;38(7):966-73. Epub 2004 Mar 16.


Supplemental Content

Loading ...
Support Center